Hepatitis B virus genotype C encoding resistance mutations that emerge during adefovir dipivoxil therapy: In vitro replication phenotype

Hepatology International

Volumn 7, Issue 2, 2013, Pages 443-450

  Li, Wenpeng ^a,b,c   Warner, Nadia ^b   Sozzi, Vitina ^b   Yuen, Lilly ^b   Colledge, Danni ^b   Li, Tong ^a   Zhuang, Hui ^a   Locarnini, Stephen ^b   Revill, Peter A ^b  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b VICTORIAN INFECTIOUS DISEASES REFERENCE LABORATORY   (Australia)

^c TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

Author keywords

Adefovir dipivoxil; Drug resistance mutations; Genotype C; Hepatitis B virus; In vitro replication phenotype; Secretion defect

Indexed keywords

ADEFOVIR DIPIVOXIL; COMPLEMENTARY DNA; HEPATITIS B SURFACE ANTIGEN;

ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DNA DETERMINATION; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS B VIRUS; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MOLECULAR CLONING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS LOAD; VIRUS MUTATION; VIRUS REPLICATION;

EID: 84879837277     PISSN: 19360533     EISSN: 19360541     Source Type: Journal    
DOI: 10.1007/s12072-012-9411-2     Document Type: Article

References (33)

1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 2004;11(2):97-107
2. Lupberger J, Hildt E. Hepatitis B virus-induced oncogenesis. World J Gastroenterol 2007;13(1):74-81
3. Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol 2001;2(9):533-543
4. Ayoub WS, Keeffe EB. Review article: current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011;34(10):1145-1158
5. Angus P, Vaughan R, Xiong S, et al. Resistance to adefovir dipivoxil therapy associated with the selection of a novel mutation in the HBV polymerase. Gastroenterology 2003;125(2):292-297
6. Zoulim F, Locarnini S. Hepatitis B virus resistance to nucleos(t)ide analogues. Gastroenterology 2009;137(5):1593-1608. e1-e2
7. Zoulim F, Locarnini S. Management of treatment failure in chronic hepatitis B. J Hepatol 2012;56(Suppl 1):S112-S122
8. Warner N, Locarnini S. The antiviral drug selected hepatitis B virus rtA181T/sW172*mutant has a dominant negative secretion defect and alters the typical profile of viral rebound. Hepatology 2008;48(1):88-98
9. Yeh CT, Chen T, Hsu CW, et al. Emergence of the rtA181T/ sW172*mutant increased the risk of hepatoma occurrence in patients with lamivudine-resistant chronic hepatitis B. BMC Cancer 2011;11:398
10. Lai MW, Yeh CT. The oncogenic potential of hepatitis B virus rtA181T/surface truncation mutant. Antivir Ther 2008;13(7):875-879
11. Kim BK, Revill PA, Ahn SH. HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther 2011;16(8):1169-1186
12. Lin CL, Kao JH. The clinical implications of hepatitis B virus genotype: recent advances. J Gastroenterol Hepatol 2011;26(Suppl 1):123-130
13. Warner N, Locarnini S, Kuiper M, et al. The L80I substitution in the reverse transcriptase domain of the hepatitis B virus polymerase is associated with lamivudine resistance and enhanced viral replication in vitro. Antimicrob Agents Chemother 2007;51(7):2285-2292. doi: 10.1128/AAC.01499-06.
14. Yuen KWL, Ayres A, Littlejohn M, et al. SEQHEPB: a sequence and analysis program and relational database system for chronic hepatitis B antiviral research. Antivir Res 2007;75:64-74
15. Chen RY, Edwards R, Shaw T, et al. Effect of the G1896A precore mutation on drug sensitivity and replication yield of lamivudine-resistant HBV in vitro. Hepatology 2003;37(1):27-35
16. Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology 2010;51(6):1933-1944
17. Delaney WEt, Edwards R, Colledge D, et al. Cross-resistance testing of antihepadnaviral compounds using novel recombinant baculoviruses which encode drug-resistant strains of hepatitis B virus. Antimicrob Agents Chemother 2010;45(6):1705-1713
18. Chan HL, Hui AY, Wong ML, et al. Genotype C hepatitis B virus infection is associated with an increased risk of hepatocellular carcinoma. Gut 2004;53(10):1494-1498
19. Chan HL, Wong ML, Hui AY, et al. Hepatitis B virus genotype C takes a more aggressive disease course than hepatitis B virus genotype B in hepatitis B e antigen-positive patients. J Clin Microbiol 2003;41(3):1277-1279
20. Chu CJ, Hussain M, Lok AS. Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology 2002;122(7):1756-1762
21. Liu CJ, Kao JH. Genetic variability of hepatitis B virus and response to antiviral therapy. Antivir Ther 2008;13(5):613-624
22. Wiegand J, Hasenclever D, Tillmann HL. Should treatment of hepatitis B depend on hepatitis B virus genotypes? A hypothesis generated from an explorative analysis of published evidence. Antivir Ther 2008;13(2):211-220
23. Trojan J, Stuermer M, Teuber G, Berger A, Faust D. Treatment of patients with lamivudine-resistant and adefovir dipivoxil-resistant chronic hepatitis B virus infection: is tenofovir the answer? Gut 2007;56(3):436-437
24. Patterson SJ, George J, Strasser SI, et al. Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B. Gut 2011;60(2):247-254
25. Li X, Wang L, Zhong Y, et al. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients. J Clin Microbiol 2010;48(12):4363-4369
26. Damerow H, Yuen L, Wiegand J, et al. Mutation pattern of lamivudine resistance in relation to hepatitis B genotypes: hepatitis B genotypes differ in their lamivudine resistance associated mutation pattern. J Med Virol 2010;82(11):1850-1858
27. Yang JX, Liu BM, Li XG, et al. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. Antivir Ther 2010;15(8):1171-1178
28. Yeh CT. Development of HBV S gene mutants in chronic hepatitis B patients receiving nucleotide/nucleoside analogue therapy. Antivir Ther 2010; 15(3 Pt B):471-475
29. Lai MW, Huang SF, Hsu CW, et al. Identification of nonsense mutations in hepatitis B virus S gene in patients with hepatocellular carcinoma developed after lamivudine therapy. Antivir Ther 2009;14(2):249-261
30. Liaw Y, Kao J, Piratvisuth T, et al. Asian-Pacific Consensus statement on the management of chronic hepatitis B: A 2012 update. Hepatology Int 2012. doi: 10.1007/s12072-012-9365-4.
31. Locarnini S, Bowden S. Hepatitis B surface antigen quantification: not what it seems on the surface. Hepatology 2012;56(2):411-414
32. Kim JH, Jung YK, Joo MK, et al. Hepatitis B viral surface mutations in patients with adefovir resistant chronic hepatitis B with A181T/V polymerase mutations. J Korean Med Sci 2010;25(2):257-264
33. Lee SA, Kim K, Kim H, Kim BJ. Nucleotide change of codon 182 in the surface gene of hepatitis B virus genotype C leading to truncated surface protein is associated with progression of liver diseases. J Hepatol 2012;56(1):63-69